Trial Working Group

The trial working group design new clinical trials and encourage collaborations with academic institutions and industry in establishing clinical trials in the Nordics. The group operates in close contact with the Scientific Working Group in order to integrate translational research into the clinical trials. The overarching aim is to establish innovative trials for the Nordic population while in parallel promoting scientific excellence in the Nordic academic institutions.

Members of the Trial Working Group

  • Kim Theilgaard-Mönch (Chair)

Clinic:

  • Mika Kontro, Finland
  • Sari Kytölä, Helsinki, Finland
  • Heikki Kuusanmäki, Finland
  • Martin Jädersten, Sweden
  • Sören Lehmann, Sweden
  • Anna Eriksson, Sweden
  • Waleed Mohammed, Norway
  • Anne Sophie von Krogh, Norway
  • Anne-Louise T Sørensen, Denmark

Research:

  • Krister Wennerberg, Denmark
  • Päivi Östling, Sweden
  • Jorrit Ensrink, Norway

Why a Nordic AML Group?

Recognizeable systems in Nordic countries, similar treatment traditions, one working market.

Unmet need to improve AML therapy through research and clinical trials.

Sign up for our newsletter

This field is for validation purposes and should be left unchanged.
Name(Required)
Email(Required)
Privacy(Required)